Disease: cutaneous leishmaniasis

Genomic Insights of Candida krusei, an Emerging Fungal Pathogen With Intrinsic Antifungal Resistance

Candida krusei is a yeast that causes serious bloodstream infections, particularly in people with weakened immune systems. Unlike many other fungi, it naturally resists common antifungal drugs like fluconazole, making infections hard to treat. The organism can form protective biofilms and has multiple genetic mechanisms that help it survive antifungal treatment. Researchers are exploring new drugs and treatment strategies to combat this growing health threat, especially in hospitals.

Read More »

Synergistic Effects of Cold Atmospheric Multiple Plasma Jet and Amphotericin B on Leishmania major: An In-Vitro Study

Researchers tested a new cold plasma technology combined with an existing anti-parasite drug (amphotericin B) against Leishmania parasites that cause skin infections. The cold plasma, which contains reactive chemicals, killed the parasites by triggering their programmed cell death (apoptosis) while causing minimal harm to human immune cells. When combined with the medication, the treatment was even more effective, potentially allowing lower drug doses with fewer side effects.

Read More »
Scroll to Top